» Articles » PMID: 39519254

An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable for Genomic Surveillance Within Clinical Diagnostic Settings

Abstract

Chronic Hepatitis B Virus (HBV) infection remains a significant public health concern, particularly in Africa, where the burden is substantial. HBV is an enveloped virus, classified into ten phylogenetically distinct genotypes (A-J). Tests to determine HBV genotypes are based on full-genome sequencing or reverse hybridization. In practice, both approaches have limitations. Whereas diagnostic sequencing, generally using the Sanger approach, tends to focus only on the S-gene and yields little or no information on intra-patient HBV genetic diversity, reverse hybridization detects only known genotype-specific mutations. To resolve these limitations, we developed an Oxford Nanopore Technology (ONT)-based HBV diagnostic sequencing protocol suitable for clinical virology that yields both complete genome sequences and extensive intra-patient HBV diversity data. Specifically, the protocol involves tiling-based PCR amplification of HBV sequences, library preparation using the ONT Rapid Barcoding Kit (Oxford nanopore Technologies, Oxford, OX4 4DQ, UK), ONT GridION sequencing, genotyping using genome detective software v1.132/1.133, a recombination analysis using jpHMM (26 October 2011 version) and RDP5.61 software, and drug resistance profiling using Geno2pheno v2.0 software. We prove the utility of our protocol by efficiently generating and characterizing high-quality near full-length HBV genomes from 148 residual diagnostic samples from HBV-infected patients in the Western Cape province of South Africa, providing valuable insights into the genetic diversity and epidemiology of HBV in this region of the world.

Citing Articles

Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.

Lumley S, Kent C, Jennings D, Chai H, Airey G, Waddilove E Sci Rep. 2025; 15(1):5795.

PMID: 39962085 PMC: 11832747. DOI: 10.1038/s41598-025-87721-1.


Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.

Lakshmanan K, Liu B Diagnostics (Basel). 2025; 15(2).

PMID: 39857007 PMC: 11763637. DOI: 10.3390/diagnostics15020123.

References
1.
Padidam M, Sawyer S, Fauquet C . Possible emergence of new geminiviruses by frequent recombination. Virology. 1999; 265(2):218-25. DOI: 10.1006/viro.1999.0056. View

2.
Lee H, Chang H, Yang S, Kim H . Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. J Clin Virol. 2014; 60(3):313-6. DOI: 10.1016/j.jcv.2014.03.018. View

3.
Beggel B, Neumann-Fraune M, Doring M, Lawyer G, Kaiser R, Verheyen J . Genotyping hepatitis B virus dual infections using population-based sequence data. J Gen Virol. 2012; 93(Pt 9):1899-1907. DOI: 10.1099/vir.0.043042-0. View

4.
Martin D, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P . RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics. 2010; 26(19):2462-3. PMC: 2944210. DOI: 10.1093/bioinformatics/btq467. View

5.
Ghenea A, Padureanu V, Cioboata R, Udristoiu A, Drocas A, Tieranu E . The Study of Clinical and Biochemical Parameters in Assessing the Response to the Antiviral Therapy in the Chronic Viral Hepatitis B. Medicina (Kaunas). 2021; 57(8). PMC: 8398025. DOI: 10.3390/medicina57080757. View